IPIC Message Board - Msg: 3905938

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IPIC

IPIC 0.0001000

0.0%

Aug 15 3:35 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Pancho Villa who wrote (1129)	3/31/1998 6:05:00 PM
From: Vendit™	of 1359

Just a late press statement... -------------------------------------------------------------------------------- Tuesday March 31, 5:01 pm Eastern Time Interneuron study reassesses Redux risk LEXINGTON, Mass., March 31 (Reuters) - Interneuron Pharmaceuticals Inc. said Tuesday that a study of Redux, an anti-obesity medication that was withdrawn from the market last year, found that the incidence of cardiac valve abnormalities is far less than previously reported estimates. Also, the study found no statistically significant difference between the incidence of cardiac valve abnormalities among patients who took Redux and placebo-treated patients, the company said in a statement. The findings were presented at the 47th annual scientific session of the American College of Cardiology. -------------------------------------------------------------------------------- More Quotes and News: Interneuron Pharmaceuticals Inc (Nasdaq:IPIC - news) Related News Categories: health

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next